|
ATE548357T1
(de)
*
|
2000-01-25 |
2012-03-15 |
Neurocrine Biosciences Inc |
Gonadotropin freisetzende hormon rezeptor antagonisten und ihre verwandten verfahren
|
|
ATE407679T1
(de)
*
|
2003-07-07 |
2008-09-15 |
Neurocrine Biosciences Inc |
Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
|
|
AU2004257636B2
(en)
|
2003-07-07 |
2011-01-06 |
Neurocrine Biosciences, Inc. |
Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
|
|
JP4673847B2
(ja)
*
|
2003-07-07 |
2011-04-20 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
|
|
CN102134230B
(zh)
*
|
2004-03-15 |
2019-06-28 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
|
AR065947A1
(es)
|
2007-04-06 |
2009-07-15 |
Neurocrine Biosciences Inc |
Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)
|
|
KR101506750B1
(ko)
|
2007-04-06 |
2015-03-27 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
고나도트로핀-방출 호르몬 수용체 길항제 및 그와 관련된 방법
|
|
JP2010540534A
(ja)
|
2007-09-28 |
2010-12-24 |
イントレキソン コーポレーション |
生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
|
|
US8765948B2
(en)
|
2007-11-07 |
2014-07-01 |
Neurocrine Biosciences, Inc. |
Processes for the preparation of uracil derivatives
|
|
ES2549502T3
(es)
|
2009-11-20 |
2015-10-28 |
Sk Chemicals Co., Ltd. |
Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen
|
|
EP3384930A1
(en)
|
2013-03-15 |
2018-10-10 |
AbbVie Inc. |
Compositions for use in treating heavy menstrual bleeding
|
|
EP2881391A1
(en)
|
2013-12-05 |
2015-06-10 |
Bayer Pharma Aktiengesellschaft |
Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
|
|
US10821152B2
(en)
|
2014-08-26 |
2020-11-03 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
US20190321363A1
(en)
*
|
2016-06-20 |
2019-10-24 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of elagolix sodium and its polymorph
|
|
WO2018015497A2
(en)
|
2016-07-21 |
2018-01-25 |
ObsEva S.A. |
Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
|
|
US12043558B2
(en)
|
2016-08-23 |
2024-07-23 |
Swan Analytishce Instrumente AG |
Device and method for the electrodeionization of a liquid
|
|
EP3518952A1
(en)
|
2016-09-30 |
2019-08-07 |
Myovant Sciences GmbH |
Methods of treating female infertility
|
|
FI3518932T3
(fi)
|
2016-09-30 |
2025-02-03 |
Sumitomo Pharma Switzerland Gmbh |
Eturauhassyövän hoito
|
|
DK3518933T4
(da)
|
2016-09-30 |
2025-04-22 |
Takeda Pharmaceuticals Co |
Fremgangsmåder til behandling af uterusfibromer og endometriose
|
|
ES2983735T3
(es)
|
2016-12-14 |
2024-10-24 |
Purdue Research Foundation |
Conjugados del receptor de la hormona liberadora de hormona luteinizante (LHRH-R) y usos de los mismos
|
|
EP3388421B1
(en)
|
2017-04-13 |
2019-12-04 |
Sandoz AG |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
|
|
AU2018251951B2
(en)
|
2017-04-12 |
2020-09-03 |
Sandoz Ag |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
|
|
PT3388422T
(pt)
|
2017-04-13 |
2020-02-18 |
Sandoz Ag |
Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral
|
|
WO2018198086A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Lupin Limited |
Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
|
|
KR20250117836A
(ko)
|
2017-06-05 |
2025-08-05 |
깃세이 야쿠힌 고교 가부시키가이샤 |
자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
|
|
WO2018224063A2
(en)
*
|
2017-06-08 |
2018-12-13 |
Zentiva, K.S. |
Solid forms of elagolix
|
|
WO2019036713A1
(en)
|
2017-08-18 |
2019-02-21 |
Abbvie Inc. |
SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
|
|
WO2019036712A1
(en)
|
2017-08-18 |
2019-02-21 |
Abbvie Inc. |
PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS
|
|
CN111698992A
(zh)
*
|
2017-08-18 |
2020-09-22 |
艾伯维公司 |
用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
|
|
CN107935863A
(zh)
*
|
2017-11-30 |
2018-04-20 |
厦门海乐景生化有限公司 |
Elagolix的关键原料化合物C的合成方法
|
|
CN110938037A
(zh)
*
|
2018-09-21 |
2020-03-31 |
苏州鹏旭医药科技有限公司 |
一种依拉戈利钠盐药物中间体的制备方法
|
|
WO2019112968A1
(en)
|
2017-12-05 |
2019-06-13 |
Peng Wang |
Processes to produce elagolix
|
|
EP3724167A1
(en)
|
2017-12-11 |
2020-10-21 |
Synthon B.V. |
Process for preparing elagolix
|
|
CN109970663B
(zh)
*
|
2017-12-27 |
2023-04-11 |
上海科胜药物研发有限公司 |
一种制备噁拉戈利中间体的方法
|
|
CN108129400B
(zh)
*
|
2017-12-29 |
2021-10-15 |
安帝康（无锡）生物科技有限公司 |
氘代噁拉戈利衍生物及其用途
|
|
IL278082B2
(en)
|
2018-04-19 |
2025-03-01 |
Abbvie Inc |
Methods of treating heavy menstrual bleeding
|
|
CN110669013A
(zh)
*
|
2018-07-03 |
2020-01-10 |
江苏海悦康医药科技有限公司 |
一种噁拉戈利中间体的制备方法
|
|
WO2020023459A1
(en)
|
2018-07-23 |
2020-01-30 |
Abbvie Inc. |
Elagolix sodium compositions and processes
|
|
CA3107597A1
(en)
*
|
2018-08-01 |
2020-02-06 |
Abbvie Inc. |
Dosing regimens for elagolix
|
|
EP3572406A1
(en)
|
2018-10-17 |
2019-11-27 |
Sandoz Ag |
Acid addition salt of elagolix and related compounds
|
|
EP3873465B1
(en)
|
2018-10-29 |
2025-01-15 |
Kissei Pharmaceutical Co., Ltd. |
Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
|
|
EP3876943A2
(en)
|
2018-11-07 |
2021-09-15 |
ObsEva S.A. |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
CN109293634A
(zh)
*
|
2018-12-04 |
2019-02-01 |
中国药科大学 |
恶拉戈利杂质的制备方法
|
|
CN109651171A
(zh)
*
|
2019-01-13 |
2019-04-19 |
苏州鹏旭医药科技有限公司 |
依拉戈利及其钠盐的中间体及其盐的制备方法和应用
|
|
MX2021008457A
(es)
|
2019-01-15 |
2021-10-01 |
Lupin Inc |
Composiciones de tipo elagolix deuterado y métodos.
|
|
CN109810065B
(zh)
*
|
2019-02-16 |
2022-07-15 |
安徽华胜医药科技有限公司 |
一种恶拉戈利的合成方法
|
|
CN109761913A
(zh)
*
|
2019-02-16 |
2019-05-17 |
安徽华胜医药科技有限公司 |
一种有机金属钯催化合成elagolix中间体的方法
|
|
CN109651265A
(zh)
*
|
2019-02-16 |
2019-04-19 |
安徽诺全药业有限公司 |
一种Elagolix的制备方法
|
|
CN110041232A
(zh)
*
|
2019-04-10 |
2019-07-23 |
丽珠集团新北江制药股份有限公司 |
一种制备GnRHR药物关键中间体化合物的方法
|
|
CN109956906B
(zh)
*
|
2019-04-19 |
2021-01-29 |
奥锐特药业股份有限公司 |
一种噁拉戈利关键中间体的制备方法
|
|
US20220242831A1
(en)
*
|
2019-05-24 |
2022-08-04 |
Dr. Reddy's Laboratories Limited |
Improved process for the preparation of elagolix and its intermediates
|
|
CN110204498B
(zh)
*
|
2019-06-14 |
2020-11-27 |
奥锐特药业股份有限公司 |
一种高效合成噁拉戈利中间体的方法
|
|
CN110372608A
(zh)
*
|
2019-07-09 |
2019-10-25 |
丽珠集团新北江制药股份有限公司 |
一种促性腺激素释放激素拮抗剂的制备方法
|
|
ES2802815B2
(es)
*
|
2019-07-12 |
2022-03-14 |
Moehs Iberica Sl |
Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix
|
|
CN110372609B
(zh)
*
|
2019-07-25 |
2021-04-09 |
奥锐特药业股份有限公司 |
一种噁拉戈利钠盐的纯化方法
|
|
CN112672998B
(zh)
*
|
2019-07-31 |
2022-06-21 |
深圳仁泰医药科技有限公司 |
恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途
|
|
US20220305017A1
(en)
|
2019-08-08 |
2022-09-29 |
ObsEva S.A. |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
CN114364384A
(zh)
|
2019-08-08 |
2022-04-15 |
奥布赛瓦股份公司 |
用于治疗雌激素依赖性病症的GnRH拮抗剂
|
|
IT202000001390A1
(it)
|
2020-01-24 |
2021-07-24 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
WO2021044230A1
(en)
*
|
2019-09-03 |
2021-03-11 |
Industriale Chimica S.R.L. |
Process for the synthesis of the sodium salt of 4-[[(lr)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-l(2h)-pyrimidinyl]-l- phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
|
|
CN114667141A
(zh)
|
2019-09-03 |
2022-06-24 |
奥布赛瓦股份公司 |
用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
|
|
IT201900015458A1
(it)
|
2019-09-03 |
2021-03-03 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
TWI755055B
(zh)
|
2019-09-18 |
2022-02-11 |
台灣神隆股份有限公司 |
用於製備惡拉戈利鈉及其中間體的方法
|
|
WO2021064561A1
(en)
*
|
2019-10-03 |
2021-04-08 |
Neuland Laboratories Limited |
An improved process for the preparation of elagolix sodium
|
|
CN112694445B
(zh)
*
|
2019-10-22 |
2023-07-28 |
成都倍特药业股份有限公司 |
一种噁拉戈利钠中间体的纯化方法
|
|
ES2822398B2
(es)
|
2019-10-30 |
2022-03-02 |
Moehs Iberica Sl |
3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix
|
|
US20230072265A1
(en)
*
|
2019-12-27 |
2023-03-09 |
Msn Laboratories Private Limited, R&D Center |
An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts
|
|
CN113125575B
(zh)
*
|
2019-12-31 |
2023-04-18 |
济南尚博生物科技有限公司 |
一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法
|
|
CN111116490A
(zh)
*
|
2020-01-15 |
2020-05-08 |
奥锐特药业股份有限公司 |
一种噁拉戈利中间体水杨酸盐的制备与纯化方法
|
|
WO2021160597A1
(en)
|
2020-02-10 |
2021-08-19 |
ObsEva S.A. |
Biomarkers for oxytocin receptor antagonist therapy
|
|
CN115515592A
(zh)
*
|
2020-03-05 |
2022-12-23 |
艾伯维公司 |
施用恶拉戈利的方法
|
|
WO2021180862A1
(en)
|
2020-03-12 |
2021-09-16 |
Synthon B.V. |
Pharmaceutical compositions comprising elagolix sodium
|
|
CN111333548B
(zh)
*
|
2020-04-10 |
2022-04-26 |
江苏海悦康医药科技有限公司 |
1-(2-氟-6-(三氟甲基)苄基)脲的制备方法
|
|
CN113527213B
(zh)
|
2020-04-20 |
2023-01-03 |
上海英诺富成生物科技有限公司 |
促性激素释放激素受体拮抗剂及其用途
|
|
CN113683572A
(zh)
*
|
2020-05-18 |
2021-11-23 |
陈晓雯 |
噁拉戈利的中间体及其制备方法和应用
|
|
CN113880773A
(zh)
*
|
2020-07-02 |
2022-01-04 |
南京药石科技股份有限公司 |
一种噁拉戈利中间体的制备方法
|
|
CN112457258A
(zh)
*
|
2020-11-26 |
2021-03-09 |
诚达药业股份有限公司 |
一种噁拉戈利钠及其中间体的制备方法
|
|
US20220257597A1
(en)
|
2021-01-29 |
2022-08-18 |
Abbvie Inc. |
Methods of Administering Elagolix
|
|
KR102656087B1
(ko)
|
2024-01-12 |
2024-04-09 |
주식회사 씨엠지 |
Led 소자의 에폭시 수지 코팅층 형성 방법
|